Human Papillomavirus Screening Articles & Analysis
8 news found
British Journal of Cancer; https://doi.org/10.1038/s41416-021-01614-4 Primary HPV screening has doubled the number of colposcopy referrals because of direct referral of HPV-positive women with ASC-US/ LSIL cytology. This study evaluated the CIN3+ risks and colposcopy referrals by QIAsure Methylation Test analysis HPV16/18 genotyping HPV16/18/31/33/45 genotyping in HPV-positive women ...
This year ECCMID 2021 conference is still fully virtual, nevertheless the data presented are real! Self-screen is proud to announce that the QIAGEN NeuMoDx HPV Test Strip Assay fulfills the International Guidelines for HPV Testing, the so-called Meijer criteria. The data are presented during the QIAGEN symposium on July 12th by dr. Anja Šterbenc MD, PhD from Prof. dr. Mario Poljak’s ...
During the QIAGEN symposium at Eurogin the latest clinical performance and study data around Self-screen’s molecular screening and triage solutions were presented by excellent scientists. Topic 31 May 2021: Full molecular screening and triage solutions, chaired by Prof. dr. Chris Meijer Presenters: Dr. Bart Hesselink (Self-screen B.V., Netherlands) – Clinical performance of ...
Self-screen is proud to announce the appointment of Michelle Meijer, PhD, as the companies Chief Commercial Officer. Michelle brings over 25 years of business experience in the life sciences and molecular diagnostics field, of which more than 15 years in the field of cervical cancer prevention and HPV diagnostics in particular. She held several senior business development and management roles at ...
Self-screen’s Chief Scientific Officer dr. Bart Hesselink talks about the clinical validation of QIAGEN’s next generation HPV screening assay on the NeuMoDxTM Molecular Systems. The NeuMoDxTM 288 and NeuMoDxTM96 Molecular Systems are fully automated continuous random-access analyzers that perform adequately in standardized, high volume cervical cancer HPV screening laboratories. The ...
The initial project in this expanded collaboration focuses on the co-development of a diagnostic test that identifies women who are most likely to benefit from clinical use of VGX-3100, INOVIO's immunotherapy to treat advanced cervical dysplasia associated with the human papillomavirus (HPV). QIAGEN's bioinformatic expertise will further increase the predictive ...
With the introduction of HPV based screening in 2017 the Dutch cervical cancer screening program underwent an important improvement. More women at risk are being discovered due to the higher sensitivity of HPV assays compared to the old cytology based test program, but as a consequence the number of referrals after cytology based triage of HPV positive women has increased 3 times. The ...
Approximately 26,000 human papillomavirus (HPV) tests will go to the Nargis Dutt Memorial Cancer Hospital for cervical cancer screening, the company said at the Women Deliver global advocacy conference in Washington DC, which is focused on promoting global maternal health solutions. ...